A5019710723- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Monoclonal and Polyclonal Antibodies Research
- Autoimmune and Inflammatory Disorders Research
- Spondyloarthritis Studies and Treatments
- Systemic Sclerosis and Related Diseases
- Cardiovascular Conditions and Treatments
- Atherosclerosis and Cardiovascular Diseases
- Lymphoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Congenital Heart Disease Studies
- Bone and Joint Diseases
- Musculoskeletal Disorders and Rehabilitation
- Peripheral Neuropathies and Disorders
- Vasculitis and related conditions
- Health and Medical Studies
- Immunodeficiency and Autoimmune Disorders
- Cardiac Arrhythmias and Treatments
- Chronic Lymphocytic Leukemia Research
- Agricultural Economics and Policy
- Urticaria and Related Conditions
- Cytokine Signaling Pathways and Interactions
- Musculoskeletal synovial abnormalities and treatments
- Viral Infections and Immunology Research
- Immune Cell Function and Interaction
Justus-Liebig-Universität Gießen
2016-2025
Düsseldorf University Hospital
2015-2024
Heinrich Heine University Düsseldorf
2015-2024
University Hospital Bonn
2021-2024
St. Elisabeth Hospital
2024
University Hospital of Basel
2010-2023
Université Laval
2023
Toronto General Hospital
2023
Toronto General Hospital Research Institute
2023
University of Cambridge
2023
To develop new classification criteria for systemic lupus erythematosus (SLE) jointly supported by the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR).This international initiative had four phases. 1) Evaluation antinuclear antibody (ANA) as an entry criterion through systematic review meta-regression literature generation Delphi exercise, early patient cohort, a survey. 2) Criteria reduction nominal group technique exercises. 3) definition weighting...
Our objective was to update the EULAR recommendations for management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity prevention flares. Hydroxychloroquine is recommended all patients with lupus, dose not exceeding 5 mg/kg real body weight. During chronic...
Objectives To develop recommendations for the management of adult and paediatric lupus nephritis (LN). Methods The available evidence was systematically reviewed using PubMed database. A modified Delphi method used to compile questions, elicit expert opinions reach consensus. Results Immunosuppressive treatment should be guided by renal biopsy, aiming complete response (proteinuria <0.5 g/24 h with normal or near-normal function). Hydroxychloroquine is recommended all patients LN. Because...
<h3>Objective:</h3> Systemic lupus erythematosus (SLE) is a complex disease with variable presentations, course and prognosis. We sought to develop evidence-based recommendations addressing the major issues in management of SLE. <h3>Methods:</h3> The EULAR Task Force on SLE comprised 19 specialists clinical epidemiologist. Key questions for were compiled using Delphi technique. A systematic search PubMed Cochrane Library Reports was performed McMaster/Hedges queries' strategies related...
Objectives To develop recommendations for the diagnosis, prevention and treatment of neuropsychiatric systemic lupus erythematosus (NPSLE) manifestations. Methods The authors compiled questions on prevalence risk factors, diagnosis monitoring, therapy prognosis NPSLE. A systematic literature search was performed evidence categorised based sample size study design. Results Systemic (SLE) patients are at increased several Common (cumulative incidence >5%) manifestations include...
Abstract Objective To estimate the incidence rates of serious and nonserious infections in patients with rheumatoid arthritis (RA) who start treatment a biologic agent, to compare these those RA receive conventional treatment. Methods Patients enrolled German biologics register between May 2001 September 2003 were included. Treating rheumatologists assessed adverse events events. All experienced within 12 months after study entry analyzed. Propensity score methods applied which part rate...
Objective To update the 2012 EULAR/ERA–EDTA recommendations for management of lupus nephritis (LN). Methods Following EULAR standardised operating procedures, a systematic literature review was performed. Members multidisciplinary Task Force voted independently on their level agreeement with formed statements. Results The changes include treatment targets, use glucocorticoids and calcineurin inhibitors (CNIs) end-stage kidney disease (ESKD). target therapy is complete response (proteinuria...
Objectives To update the EULAR recommendations for management of systemic lupus erythematosus (SLE) based on emerging new evidence. Methods An international Task Force formed questions systematic literature reviews (January 2018–December 2022), followed by formulation and finalisation statements after a series meetings. A predefined voting process was applied to each overarching principle recommendation. Levels evidence strengths recommendation were assigned, participants finally provided...
<h3>Objective</h3> To examine the risk of serious infection conveyed by tumour necrosis factor α (TNFα) inhibitors in treatment rheumatoid arthritis (RA). <h3>Methods</h3> Data from patients with RA enrolled German biologics register RABBIT were used for analysis. Baseline patient characteristics, time-varying factors (treatment changes, functional capacity) and selection processes caused dropout, death or switching to non-anti-TNF taken into account estimate adjusted incidence rate ratios...
Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but has been lacking. Previously, an international task force consisting representatives medical specialists published framework such definition, without reaching final recommendation. Methods Several systematic literature reviews were performed specific research questions examined suitably chosen data sets. The findings discussed, reformulated...
Abstract Objective Treatment of ankylosing spondylitis (AS) with infliximab, an anti–tumor necrosis factor α monoclonal antibody, was shown to be efficacious in patients active disease during a 3‐month treatment period. The purpose this study evaluate the efficacy and safety infliximab AS for 1‐year Methods This open, observational, extension 3‐month, randomized, placebo‐controlled trial. All who had tolerated (infliximab/infliximab group) or placebo (placebo/infliximab 12‐week crossover...
Background: Myxomatous mitral valve disease (MMVD) continues to be an important cause of morbidity and mortality in geriatric dogs despite conventional therapy. Hypothesis: Pimobendan addition therapy will extend time sudden cardiac death, euthanasia for reasons, or treatment failure when compared with plus benazepril congestive heart (CHF) attributable MMVD. Animals: Two hundred sixty client‐owned CHF caused by MMVD were recruited from 28 centers Europe, Canada, Australia. Methods: A...
Abstract Objective Randomized clinical trials (RCTs) evaluate the efficacy of treatments in selected groups patients defined by strict inclusion criteria. The value these predicting therapeutic effectiveness “real world” is limited. This observational cohort study was designed to complement knowledge obtained RCTs evaluating tumor necrosis factor (TNF) inhibitors with rheumatoid arthritis (RA) according their eligibility for major trials. Methods Using data from German biologics register...
Current therapeutic and diagnostic resources have turned systemic lupus erythematosus (SLE) into a chronic disease by reducing mortality rates. The exact contribution of activity related damage to is not well studied. aim this study was describe the current causes death (COD) in multinational European cohort patients with SLE relation quantified measures damage. Prospective five-year observational case fatalities at 12 centres performed. Demographics, manifestations, interventions (by ECLAM...
Abstract Objective To determine the hazard risk of developing or worsening heart failure in rheumatoid arthritis (RA) patients treated with tumor necrosis factor α (TNFα) inhibitors. Methods RA ages 18–75 years who started treatment infliximab, etanercept, adalimumab (n = 2,757), conventional disease‐modifying antirheumatic drugs (controls; n 1,491) at time enrollment a German biologics register were studied. Cox proportional hazards models applied to investigate influence disease‐related...
Objective. Infliximab, a monoclonal antibody against tumour necrosis factor α (TNF-α), is approved in Europe for the treatment of patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. This report provides analyses from 3-yr extension study, as follow-up both 1- and 2-yr open label extensions original 3-month randomized controlled trial infliximab AS.
An inception cohort of patients with systemic lupus erythematosus from 14 European centres was followed for up to 5 years in order describe the current early disease course. At inclusion (n = 200, 89% female, mean age 35 years, 97% Caucasian, SLEDAI 12.2) fulfilled a 6.5 ACR classification criteria. The most prevalent criteria were antinuclear Ab presence (97%) by anti-dsDNA (74%), arthritis (69%), leukocytopenia (54%) and malar rash (53%), antiphospholipid (48%) anti-synovial membrane...